Browsing Tag
Eli Lilly and Company
145 posts
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Eli Lilly’s Jaypirca outpaces Imbruvica in landmark CLL head‑to‑head trial
Eli Lilly’s Jaypirca beats Imbruvica in a head-to-head CLL trial. Explore why this breakthrough matters for BTK therapy and cancer care.
Is Eli Lilly the NVIDIA of healthcare? How metabolic drugs became the new AI trade
Discover how Eli Lilly and Company crossed the $1 trillion valuation mark and why its metabolic-health franchise is now being valued like a high-growth tech platform—read more now.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
MeiraGTx signs $475m ophthalmology gene therapy collaboration with Eli Lilly
MeiraGTx Holdings plc signed a USD 475 million gene therapy deal with Eli Lilly and Company to develop AAV-AIPL1 and apply riboswitch tech in ophthalmology.
Eli Lilly (NYSE: LLY) to build $3bn Netherlands plant to power global obesity drug supply
Find out how Eli Lilly’s $3 billion Netherlands plant will reshape obesity drug manufacturing and strengthen Europe’s pharma supply chain resilience.
Will orforglipron turn Eli Lilly into the king of GLP-1s? The FDA decision that could change obesity care
Eli Lilly is stockpiling orforglipron pills ahead of FDA approval. Explore the risks, rewards, and why investors are paying close attention to this launch.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?